CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

19-386/S017

Trade Name: Brevibloc Injection 2500mg/ML and 100mg/10mL

Generic Name: Esmolol Hydrochloride

Sponsor: Baxter Pharmaceutical Products Inc.

Approval Date: January 26, 2001

Indications: Short-Term control of heart rate in patients with abnormally fast heart rhythms such as artrial fibrillation, atrial flutter or sinus tachycardia.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-386/Supplement 17

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-386/S017

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-386/S-017

Baxter Pharmaceutical Products Inc.
Attention: Priya Jambhekar
95 Spring Street
New Providence, NJ 07974

Dear Ms. Jambhekar:

Please refer to your supplemental new drug application dated July 28, 2000, received July 31, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Brevibloc (esmolol HCl) Injection, 2500 mg/10 mL and 100 mg/10mL.

This "Changes Being Effected in 30 days" supplemental new drug application provides for revised HPLC methods for assay and impurities in the drug substance and drug product.

We have completed the review of this supplemental application, and it is approved. Please note that the proposed specification limit of —— for the degradation product, ————, is unacceptably high. Please refer to our 'Approvable' letter of December 29, 2000 for NDA 19-386/S-018 and tighten the acceptance criterion for ———— in the drug product specifications.

In order to facilitate validation of the regulatory methods please submit a complete methods validation package. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Zelda McDonald, Regulatory Health Project Manager, at (301) 594-5333.

Sincerely,

{See appended electronic signature page}

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I for the
Division of Cardio-Renal Drug Products, (HFD-110)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research

/s/

Kasturi Srinivasachar
1/26/01 04:19:05 PM

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-386/S017

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW	1. ORGANIZATION HFD-110	2. NDA Number 19–386
3. Name and Address of Applicant (City & State) Baxter Pharmaceutical Products Inc. 95 Spring Street New Providence, NJ 07974		4. Supplement(s) Number(s) Date(s) SCP/017 07/28/00
5. Drug Name Brevibloc	6. Nonproprietary Name Esmolol HCl	7. Amendments & Other (reports, etc) Dates
8. Supplement Provides For: Revised HPLC methods for assay and impurities of drug substance and drug product and revised specifications that include these revised methods.		
9. Pharmacological Category Anti–adrenergic (β receptor)	10. How Dispensed ☒Rx ☐OTC	11. Related IND(s)/ NDA(s)/DMF(s)
12. Dosage Form(s) Intravenous injection	13. Potency(ies) 250mg/mL 10mL amp 10 mg/mL 10mL vial	
14. Chemical Name and Structure methyl p–[2–hydroxy–(isopropylamino)propoxy] hydrocinnamate hydrochloride  HCl		15. Records/Reports Current ☒Yes ☐No Reviewed ☒Yes ☐No

16. **Comments:**
Firm has provided the single HPLC method ———— for drug substance that replaces 3 old analytical methods for assay and impurities ———— Also single analytical method ———— for drug product that replaces the approved analytical method for assay and provides for the determination of the degradation product ————
Firm has shown that these revised methods provide the equivalent results with the approved methods and also validated these methods for use in the release and stability testing of the drug products.

Cont'd

17. **Conclusions and Recommendations**
The chemistry data is satisfactory. This supplement may be approved.

18. **REVIEWER**

Name	Signature	Date Completed
JV Advani		January. 24, 2001

Distribution: ☒ Original Jacket ☒ Reviewer ☒ Division File ☒ CSO

3 Page(s) Withheld

X § 552(b)(4) Trade Secret / Confidential

___ § 552(b)(5) Deliberative Process

___ § 552(b)(4) Draft Labeling

/s/

J. V. Advani
1/25/01 09:44:39 AM
CHEMIST

Kasturi Srinivasachar
1/25/01 10:50:39 AM
CHEMIST